Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.05, Briefing.com reports.

Atara Biotherapeutics (NASDAQ:ATRA) opened at 13.35 on Friday. Atara Biotherapeutics has a 1-year low of $11.80 and a 1-year high of $23.40. The stock’s 50 day moving average is $14.97 and its 200-day moving average is $15.91. The firm’s market capitalization is $407.96 million.

A number of brokerages recently weighed in on ATRA. ValuEngine lowered shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $25.75.

COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/19/atara-biotherapeutics-inc-nasdaqatra-posts-earnings-results-misses-expectations-by-0-05-eps-updated.html.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 6,900 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $13.35, for a total transaction of $92,115.00. Following the transaction, the chief executive officer now owns 731,859 shares of the company’s stock, valued at $9,770,317.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 3,450 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $13.44, for a total transaction of $46,368.00. Following the transaction, the chief executive officer now directly owns 731,859 shares in the company, valued at approximately $9,836,184.96. The disclosure for this sale can be found here. Insiders have sold 52,059 shares of company stock worth $752,211 in the last ninety days. Insiders own 16.10% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Earnings History for Atara Biotherapeutics (NASDAQ:ATRA)

What are top analysts saying about Atara Biotherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Atara Biotherapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit